H19

H19 is a conserved long noncoding RNA (lncRNA) transcribed from the imprinted 11p15.5 locus in humans. It is expressed monoallelically from the maternal allele and functions in cis and trans to influence growth, development, and epigenetic regulation. H19 has been studied across models including Mus musculus, Homo sapiens clinical cohorts, and diverse cell lines, linking it to imprinting control, growth factor signaling, and cancer biology.

Description and Genomic Features

H19 resides in the 11p15.5 imprinting cluster adjacent to the insulin-like growth factor 2 gene, flanked by imprinting control elements characterized in studies involving Beckwith–Wiedemann syndrome and Silver–Russell syndrome. The locus contains differentially methylated regions first mapped in genome-wide methylation surveys that employed techniques used by groups at Harvard University, Wellcome Trust Sanger Institute, and National Institutes of Health. The H19 transcript is a ~2.3 kb spliced, capped, polyadenylated lncRNA lacking an extended open reading frame, with secondary structure features identified using methodologies developed at Max Planck Institute for Molecular Genetics and Cold Spring Harbor Laboratory. Chromatin profiling experiments using ChIP-seq datasets from consortia like the ENCODE Project and the Roadmap Epigenomics Project reveal promoter marks such as H3K4me3 and enhancer-associated modifications in tissue-specific contexts. The imprinting control region (ICR) upstream is bound by factors including CTCF and components of the cohesin complex, and its methylation status is maintained by DNA methyltransferases such as DNMT1 and DNMT3A.

Expression and Regulation

H19 expression is high in embryonic tissues and downregulated postnatally in many organs, based on RNA-seq atlases produced by GTEx Consortium and developmental transcriptome maps from ENCODE. Maternal allele-specific expression depends on allele-specific DNA methylation and chromatin architecture; allele-specific assays developed at institutions like Stanford University and MIT demonstrated this imprinting. Regulation involves transcription factors and noncoding regulators including binding by CTCF, modulation by the long-range interaction network involving IGF2 enhancers, and control by microRNA pathways where H19 serves as a precursor for miR-675, characterized in studies from University of Cambridge and University of California, San Diego. Post-transcriptional control includes RNA-binding proteins such as HuR and components of the RNA-induced silencing complex, with stability and localization influenced by nucleocytoplasmic transport proteins described in research from European Molecular Biology Laboratory.

Biological Functions and Mechanisms

H19 acts through multiple mechanisms: as a precursor for microRNA biogenesis (miR-675), as a molecular scaffold modulating chromatin modifiers like EZH2 of the Polycomb Repressive Complex 2, and as a competitive endogenous RNA interacting with microRNAs studied by groups at Johns Hopkins University and UCSF. Functional studies in Mus musculus knockout and transgenic models from laboratories at Princeton University and Cold Spring Harbor Laboratory indicate roles in regulating fetal and placental growth via antagonism of IGF2 signaling and modulation of growth factor pathways involving PI3K-AKT components. H19 also influences cellular processes such as proliferation, apoptosis, and differentiation through interactions with signaling mediators studied in cancer research centers including MD Anderson Cancer Center and Dana–Farber Cancer Institute.

Role in Development and Imprinting

During embryogenesis H19 contributes to growth regulation in organs such as the liver, skeletal muscle, and placenta; developmental expression patterns were delineated by embryology groups at UCL Institute of Child Health and University of Tokyo. Imprinting at the H19/IGF2 domain exemplifies parent-of-origin epigenetic control first elucidated through classic experiments in Mus musculus and later characterized in human pedigrees with imprinting disorders investigated at Great Ormond Street Hospital and Oxford University. Maintenance of imprinting involves germline establishment in primordial germ cells, protection of methylation marks by zinc-finger proteins like ZFP57, and chromatin boundary functions mediated by CTCF. Disruption of these processes alters enhancer-promoter interactions affecting IGF2 expression, with developmental consequences observed in animal models and human syndromes.

Clinical Significance and Disease Associations

Aberrant H19 expression or imprinting is associated with overgrowth and growth-restriction disorders including Beckwith–Wiedemann syndrome and Silver–Russell syndrome, where diagnostic methylation assays developed at clinical genetics centers such as Mayo Clinic and Great Ormond Street Hospital are applied. H19 dysregulation appears in multiple cancers—breast, liver, colorectal, and bladder—reported in studies from Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and National Cancer Institute; it can act as an oncogenic lncRNA or tumor suppressor depending on context. Somatic and epigenetic alterations at the locus are investigated for biomarker potential in liquid biopsy initiatives led by European Society for Medical Oncology collaborators. Therapeutic targeting efforts include antisense oligonucleotides, CRISPR-based epigenome editing pioneered at Broad Institute, and miRNA-directed strategies explored in preclinical studies at Novartis and academic translational centers.

Category:Long noncoding RNA Category:Imprinting